Pounding the table

Now that technical analysis has chimed in on NNVC, what is the fundamental story?  Especially for new readers of AllAllan who have arrived here in search of the holy grail Trend Following Model, below is an excellent summary of the case for NNVC, taken from a recent post at the iHub NNVC forum.


 From iHub NNVC Forum

"I just sent the following to Jeff Tannenbaum at Bloomberg:

"Hi Jeff,


"Just read your article on Bloomberg regarding the flu. Nice work. Although I'm not in the medical field (other than having been an EMT years ago), I am an interested investor who immerses myself into promising technologies. In this case, I'd like to bring to your attention a Connecticut based company by the name of Nanoviricides (NNVC:OTC) that is making some impressive strides on many fronts in the area of virology. Techno-babble aside, here's how it works. The company has developed a nano-sized polymer to which it attaches what is known as a targeting ligand. The ligand acts as bait to the targeted virus by making the virus believe it is a cell it is supposed to infect. Once the virus binds to the ligand, the polymer then envelopes the virus and dissolves its capsid (the outer membrane) thereby destroying the virus.


"The company is nearing completion of animal studies on herpes HSV-1 and 2 (with a 99.99% reduction of viral load), Epidemic Keratoconjunctivitis (viral pink eye) (the only treatment that resolved disease in rabbit models), rabies (which is 100% fatal once signs appear; however, in this case a 30% survival rate), and HIV (demonstrated superior efficacy in mouse models to current HAART drug combo in use today with no side effects).


"In addition the company is in Pre-cinical testing with drugs for H5N1, H1N1 and all other influenzas, ebola, and dengue fever.


"What makes these drugs so novel is that unlike vaccines, nanoviricides do not rely on the subject's immune system to mount an immune response. They simply circulate in the bloodstream looking for viruses to destroy. This is particularly important for end-stage AIDS patients whom have no immune system left to stimulate. The other interesting feature is that nanoviricides are broad spectrum thereby preventing viruses to escape via mutation.


"The company has been involved with the most prestigious governmental and nonprofit educational/health research institutions throughout the United States and abroad for the past few years. Following are news and PRs of recent accomplishments. What amazes me about this company is that with so much in works, it remains under the radar. As a matter of disclosure, I currently own no shares in the company; however, I will be reinvesting once the company moves into human testing and announces favorable toxicology results in humans. If successful, this will change the paradigm of viral treatments."

xxxxxxxxxxxxx

NanoViricides, Inc. Reports that HIVCide-I Was Significantly Superior to the Current Anti-HIV Three Drug Cocktail Standard
The Novel Mechanism of Action of HIVCide-I Defines a New Class of Anti-HIV Drugs -Monday August 11, 7:00 am ET

http://www.nanotechwire.com/news.asp?nid=6461

NanoViricides, Inc. Signs Rabies Agreement with CDC for Expanded Research
Study to Evaluate Usage Strategy for further Development towards Drug Approval -Monday August 4, 7:00 am ET

http://www.nanotechwire.com/news.asp?nid=6414

NanoViricide's EKC Eye Drug Candidate Stopped Clinical Conjunctivitis Pathology
Statistical Data Analysis Revealed Excellent Efficacy Using Clinical Scores in Animal Study; Confirmed Photographic Findings

http://www.medicalnewstoday.com/articles/115204.php

NanoViricides in Discussions with Pharma about EKC Eye Drug Candidate
Non-Disclosure Agreements Signed; Meetings Scheduled, says Company

http://www.drugs.com/clinical_trials/nanoviricides-discussions-pharma-ekc-eye-candidate-4445.html

NanoViricides' EKC Eye Drug Demonstrates Significant Therapeutic Efficacy in Initial Animal Trials
First Treatment Success against a Non-Enveloped Virus

www.reuters.com/article/pressRelease/idUS103906+19-May-2008+BW20080519

Anti-HIV NanoViricide Drug Candidate Demonstrates Significant Therapeutic Efficacy in Animal Trials
Positive Initial Results Pave the Way for Definitive Follow-Up Studies

nanotechwire.com/news.asp

Nanoviricides Found Highly Effective against Ebola by USAMRIID

http://news.moneycentral.msn.com/ticker/article.aspx?symbol=US:NNVC&feed=BW&date=20080219&id=8205799

WallStreetWeek.com Interview with Eugene Seymour, MD, MPH Chief Executive Officer NNVC

http://www.wallstreetreporter.com/page.php?page=featured&tab=2&id=27515

Link to transcripted highlights of the WallStreetWeek.com interview

http://investorshub.advfn.com/boards/read_msg.asp?message_id=24596813

New Images Show Virus Dismantled by Broad-Spectrum NanoViricides
Electron Micrographs Confirm Virus Destruction
Thursday May 31, 5:45 pm ET
findarticles.com/p/articles/mi_m0EIN/is_2007_May_31/ai_n19376822
NanoViricides Drug Effectiveness Confirmed against Rabies and Influenzas

http://www.nanotechwire.com/news.asp?nid=5251&ntid=&pg=40

Nanoviricides, Inc. and U.S. Defense Dept. Agency
Sign Joint Research and Development Agreement to Fight Dengue Fever
Dengue Fever Treatment R&D Comes as Disease Surges in Hot-climate Regions
Monday April 9, 7:05 am ET

http://findarticles.com/p/articles/mi_m0EIN/is_2007_April_9/ai_n18791897

NanoViricides, Inc. Achieves Broad Success in Initial FluCide-I™ Anti-Influenza Studies;
Company Says That Nanoviricides™ is Now a Proven Platform To Attack Bird Flu

http://www.findarticles.com/p/articles/mi_m0EIN/is_2006_March_20/ai_n16109928